Canadian Journal of Cardiology最新文献

Recurrent Plaque Healing Precipitates an Exercise Test-Induced Acute Coronary Syndrome in a Young Diabetic Patient. 复发斑块愈合沉淀运动试验诱导的急性冠脉综合征的年轻糖尿病患者。

IF 5.3 2区医学

Canadian Journal of Cardiology Pub Date : 2026-05-07 DOI: 10.1016/j.cjca.2026.04.038

Liang Geng, Jie Ding, Hang Zhang, Li Jimin, Wei Guo

引用次数: 0

Assisted Reproductive Technologies in Cardiovascular Disease: From Caution to Careful Adoption. 辅助生殖技术在心血管疾病：从谨慎到谨慎采用。

IF 5.3 2区医学

Canadian Journal of Cardiology Pub Date : 2026-05-07 DOI: 10.1016/j.cjca.2026.04.039

M Luz Garagiola, Jack M Colman, Beatriz Fernandez-Campos

引用次数: 0

Pulsed Field Ablation Using Focal Contact Force-Sensing Catheters for Treatment of Recurrent Left Atrial Flutter. 病灶接触式力感应导管脉冲场消融治疗复发性左心房扑动。

IF 5.3 2区医学

Canadian Journal of Cardiology Pub Date : 2026-05-07 DOI: 10.1016/j.cjca.2026.04.037

Ligang Ding, Shangyu Liu, Le Li, Lishuang Ji, Yu Xia, Zili Liao, Lihui Zheng, Lingmin Wu, Zhicheng Hu, Tao Zhang, Xu Meng, Likun Zhou, Zhenhao Zhang, Mingqi Zheng, Yan Yao

{"title":"Pulsed Field Ablation Using Focal Contact Force-Sensing Catheters for Treatment of Recurrent Left Atrial Flutter.","authors":"Ligang Ding, Shangyu Liu, Le Li, Lishuang Ji, Yu Xia, Zili Liao, Lihui Zheng, Lingmin Wu, Zhicheng Hu, Tao Zhang, Xu Meng, Likun Zhou, Zhenhao Zhang, Mingqi Zheng, Yan Yao","doi":"10.1016/j.cjca.2026.04.037","DOIUrl":"https://doi.org/10.1016/j.cjca.2026.04.037","url":null,"abstract":"Background: While tissue contact significantly impacts pulsed field ablation (PFA) efficacy, evidence supporting contact force-guided PFA for recurrent left atrial flutter (AFL) remains scarce. This study investigates the efficacy and safety of PFA in this difficult-to-treat population compared to radiofrequency ablation (RFA).Methods: Patients with atypical AFL who had undergone at least one prior persistent AF ablation were prospectively enrolled for PFA and compared with a retrospectively analyzed control group treated with conventional radiofrequency ablation (RFA) at the same period. Coronary artery spasm risk was assessed via coronary angiography. The efficacy endpoints were recurrence of atrial arrhythmias after 3 months blanking period. The safety endpoint included severe procedure-related complications.Results: A total of 253 patients were included in this study (mean age 59, 68% being male), 119 patients received PFA treatment, 134 patients received RFA. At 12-month follow-up, the RFA group demonstrated a significant higher atrial tachyarrhythmia recurrence rate compared to the PFA group (36% vs. 24%; log-rank P = 0.027). In the multi-variable Cox regression model, PFA was linked to lower risk of the recurrence risk compared to RFA (Hazard ratio: 0.56, 95% confidential interval: 0.35-0.90, P = 0.017). Moreover, acute MI block rate in PFA group was significantly higher than in RFA group (100% vs 64%, P < 0.001). No procedure-related complications were observed, including esophageal fistula, phrenic nerve injury, and coronary artery spasm.Conclusion: In patients with refractory left AFL post-AF ablation, contact force-guided PFA appears promising and demonstrates favorable efficacy compared with conventional RFA..","PeriodicalId":9555,"journal":{"name":"Canadian Journal of Cardiology","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147863573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sirolimus-coated balloons in the Metal-Free registry: Favorable outcomes, unaddressed contemporary standards. 西罗莫司涂层气球在无金属登记：有利的结果，未解决的当代标准。

IF 5.3 2区医学

Canadian Journal of Cardiology Pub Date : 2026-05-06 DOI: 10.1016/j.cjca.2026.04.035

Artur Dziewierz, Wojciech Wańha, Tomasz Rakowski

引用次数: 0

Signal Without Certainty: Prophylactic Surgical Left Atrial Appendage Exclusion in Sinus Rhythm. 信号不确定：窦性心律患者预防性手术左心耳排除。

IF 5.3 2区医学

Canadian Journal of Cardiology Pub Date : 2026-05-06 DOI: 10.1016/j.cjca.2026.04.036

Jeffrey H Shuhaiber

引用次数: 0

Outcomes of Prasugrel versus Ticagrelor Following Percutaneous Coronary Intervention for Coronary Artery Disease. 经皮冠状动脉介入治疗冠心病后普拉格雷与替格瑞的疗效比较

IF 5.3 2区医学

Canadian Journal of Cardiology Pub Date : 2026-05-06 DOI: 10.1016/j.cjca.2026.04.033

Hritvik Jain, Nandan Patel, Jyoti Jain, Akshat Banga, Siddharth P Agrawal, Andrew M Goldsweig, Ann Gage, Alexander G Truesdell, J Dawn Abbott, Saraschandra Vallabhajosyula

引用次数: 0

Epidemiologic Implications of the 2025 Hypertension Canada Guideline on Hypertension Prevalence, Treatment and Control: A Population-based Cohort Study. 2025年加拿大高血压指南关于高血压患病率、治疗和控制的流行病学意义：一项基于人群的队列研究

IF 5.3 2区医学

Canadian Journal of Cardiology Pub Date : 2026-05-06 DOI: 10.1016/j.cjca.2026.04.034

Victoria Ivensky, Gregory L Hundemer, Alexander A Leung, Ross T Tsuyuki, Rémi Goupil

{"title":"Epidemiologic Implications of the 2025 Hypertension Canada Guideline on Hypertension Prevalence, Treatment and Control: A Population-based Cohort Study.","authors":"Victoria Ivensky, Gregory L Hundemer, Alexander A Leung, Ross T Tsuyuki, Rémi Goupil","doi":"10.1016/j.cjca.2026.04.034","DOIUrl":"https://doi.org/10.1016/j.cjca.2026.04.034","url":null,"abstract":"Background: In 2025, Hypertension Canada published a new guideline for the management of hypertension in primary care. Key changes included the adoption of lower blood pressure (BP) thresholds for hypertension diagnosis, treatment initiation, and treatment target. This study sought to evaluate the potential epidemiological impacts of the 2025 Hypertension Canada guideline and its implications for Canadian adults.Methods: Using data from the population-based CARTaGENE cohort, we compared how transitioning from the 2020 to the 2025 Hypertension Canada guideline recommendations could impact hypertension prevalence, indications for antihypertensive treatment, and BP control rates.Results: 16,825 participants were included in the study. Implementation of the 2025 Hypertension Canada guideline increased the number of individuals with hypertension from 7,005 (41.6%) to 8,564 (50.9%, 95% CI, 50.2 to 51.6%), primarily affecting younger participants and those at low-to-moderate cardiovascular risk. For these individuals, initial non-pharmacological management focused on lifestyle optimization would be recommended. The need for antihypertensive treatment initiation increased by only 1.3% (95% CI 0.3 to 2.4%) and predominantly concerned individuals at high cardiovascular risk. Among treated participants, BP control rates decreased by 8.7% in the low-to-moderate risk group and increased by 9.9% in the high-risk group.Conclusion: Adoption of the 2025 Hypertension Canada guideline will substantially increase the prevalence of hypertension among 40-69 year-old Canadians. Non-pharmacological interventions are recommended for all individuals; however, new antihypertensive pharmacotherapy would be recommended for only a small subset, largely limited to those at high cardiovascular risk.","PeriodicalId":9555,"journal":{"name":"Canadian Journal of Cardiology","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147855928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Translating Phenotype-Driven Pulmonary Embolism Care to the Bedside: Logistical Realities and Unmeasured Confounders. 翻译表型驱动的肺栓塞护理到床边：后勤现实和未测量的混杂因素。

IF 5.3 2区医学

Canadian Journal of Cardiology Pub Date : 2026-05-04 DOI: 10.1016/j.cjca.2026.04.031

Jakub Stępniewski, Grzegorz Kopeć

引用次数: 0

Toward Foundation Models in Cardiology. 迈向心脏病学基础模型。

IF 5.3 2区医学

Canadian Journal of Cardiology Pub Date : 2026-05-02 DOI: 10.1016/j.cjca.2026.04.030

Dor Hadida Barzilai, Alon Gorenshtein, Yiftach Barash, Mahmud Omar, Daor Hayu, Eyal Klang

引用次数: 0

Outcome Monitoring and Intermediate End Points for Gene Therapy 基因治疗的结局监测和中间终点。

IF 5.3 2区医学

Canadian Journal of Cardiology Pub Date : 2026-05-01 Epub Date: 2025-12-02 DOI: 10.1016/j.cjca.2025.11.042

Deni Kukavica MD, PhD , Alessandro Trancuccio MD, PhD , Gabriel Brooks MD , Silvia G. Priori MD, PhD

{"title":"Outcome Monitoring and Intermediate End Points for Gene Therapy","authors":"Deni Kukavica MD, PhD , Alessandro Trancuccio MD, PhD , Gabriel Brooks MD , Silvia G. Priori MD, PhD","doi":"10.1016/j.cjca.2025.11.042","DOIUrl":"10.1016/j.cjca.2025.11.042","url":null,"abstract":"<div><div>Gene therapy, a technique that seeks to modify or manipulate the expression of a gene or to alter the biological properties of living cells for therapeutic use, has evolved significantly. The design of gene therapy clinical trials, and in particular outcome monitoring and end point design, is of paramount clinical, scientific, and regulatory relevance, with practical, ethical, and financial implications for health care systems and society at large. Gene therapies are potentially irreversible, which demands that principal effects of the drug on the disease pathophysiology as well as clinical meaningfulness of the therapy, via end point specification, is well defined and measured reliably. Considering that gene therapy trials typically target rare disease and/or are resource-intensive, the sample sizes are limited, which creates a unique set of challenges. This further demands careful selection in the choice of the appropriate and feasible end points, best determined through multidisciplinary discussions that take into consideration the most appropriate statistical approach for the data analysis. In this review, we discuss the framework necessary for rational and robust outcome monitoring for gene therapy trials, and we review the currently used end points for gene therapy trials.</div></div>","PeriodicalId":9555,"journal":{"name":"Canadian Journal of Cardiology","volume":"42 5","pages":"Pages 949-966"},"PeriodicalIF":5.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145676610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0